Back to Search
Start Over
Recombinant human FGF-2 therapy for osteonecrosis of the femoral head: 5-year follow-up.
- Source :
-
Regenerative medicine [Regen Med] 2020 Nov; Vol. 15 (11), pp. 2261-2271. Date of Electronic Publication: 2020 Dec 01. - Publication Year :
- 2020
-
Abstract
- Aim: To evaluate the 5-year outcomes from the prospective study of recombinant human FGF-2 (rhFGF-2) for osteonecrosis of the femoral head (ONFH). Methods: Ten patients (average age 39.8 years) with nontraumatic, precollapse ONFH were percutaneously administered with 800 μg rhFGF-2 contained in gelatin hydrogel. Radiological changes and the prevalidated Harris hip score (HHS), visual analogue scale for pain and University of California, Los Angeles activity-rating scale scoring systems were evaluated. Results: The 5-year comparison in type C2 showed higher joint preservation in the rhFGF-2 group (71.4%) than in the natural course group (15.4%). Two of three clinical scores (Harris hip score and visual analogue scale for pain) improved significantly. Postoperative MRI demonstrated significant reduction in ONFH size. There were no adverse events. Conclusion: rhFGF-2 treatment for ONFH appears to be safe and effective and may have the potential to prevent disease progression.
Details
- Language :
- English
- ISSN :
- 1746-076X
- Volume :
- 15
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Regenerative medicine
- Publication Type :
- Academic Journal
- Accession number :
- 33256551
- Full Text :
- https://doi.org/10.2217/rme-2020-0148